longbridgelongbridge
  • Platform Features
    Features
    Investment ProductsPrivate Wealth ManagementTrading ToolsMarket Data ServicesAnalysis ToolsNews ServicesFor Developers
    Account Types
    For IndividualsFor Institutions
  • Café
longbridge
© 2026 Longbridge|Terms of ServicePrivacy Policy

Prelude Therapeutics

PRLD

----
Start trading
OverviewOverviewNewsNewsPostsPostsFinancialsFinancialsForecastForecastValuationValuationShareholdersShareholdersProfileProfile
LongbridgeAI

Current ValuationThe current P/E ratio is -6.03, below the reasonable range, cheaper than 93.86% of the time in the past 5 years, and the industry ranks 386/601, the industry Median -2.38.

-6.03xP/E
$4.57Stock price
$-0.76Earnings per share
-6.03xP/E
Stock price$4.57Earnings per share$-0.76

Historical Valuation

P/E ratioTypical rangeMedian
P/E ratio
-2.04x
Typical range
-3.03x–-0.79x

Peer P/E ratio Comparison

It displays how the company's P/E ratio compares to top companies within its industry.
019385776

The industry median valuation is currently at or below 0 and may not serve as a meaningful benchmark.

Industry P/E ratio Comparison

This shows the distribution of companies by P/E ratio range and their projected earnings per share growth for the next fiscal year.
0x30x60x90x120x150x
P/E ratio
Name/Symbol
GILDUSGilead Sciences
-57.75x148.77%$187.10B
MRNAUSModerna
-20.03x15.47%$63.11B
CSLLYUSCSL Limited
-23.57x--$60.78B
NTRAUSNatera
-274.51x10.38%$52.80B
RVMDUSRevolution Medicines
-23.87x64.29%$42.21B
ROIVUSRoivant Sciences
-108.46x145.04%$28.88B
INSMUSInsmed
-30.93x74.48%$27.07B
BNTXUSBioNTech SE
-12.66x19.17%$24.78B
SMMTUSSummit Therapeutics
-16.51x18.58%$14.14B
BBIOUSBridgebio Pharma
-19.02x28.57%$13.16B
MDGLUSMadrigal Pharma
-37.98x50.86%$12.35B
TWSTUSTwist Bioscience
-74.91x24.61%$10.24B
KYMRUSKymera Therapeutics
-32.88x4.94%$9.85B
CYTKUSCytokinetics
-10.87x6.37%$9.72B
ARWRUSArrowHead Pharma
-29.91x36,308.30%$9.57B
ABVXUSAbivax SA
-24.03x32.59%$9.33B
PCVXUSVaxcyte
-8.44x48.80%$8.98B
IBRXUSImmunityBio
-9.04x152.63%$8.97B
PRAXUSPraxis Precision Medicines
-25.56x3.05%$8.67B
SYREUSSpyre Therapeutics
-54.40x47.81%$8.17B

Risk Warning

Timeframes using financial data from S&P Global. The feature provides key metrics such as price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S) ratios, and dividend yield. For reference only and does not constitute investment advice.